How have OGEN shares performed in 2024?

Oragenics' stock was trading at $6.1382 on January 1st, 2024. Since then, OGEN stock has decreased by 81.3% and is now trading at $1.15. View the best growth stocks for 2024 here .

How were Oragenics' earnings last quarter?

Oragenics, Inc. (NYSE:OGEN) announced its quarterly earnings data on Friday, March, 29th. The company reported ($5.48) earnings per share for the quarter.

When did Oragenics' stock split?

Oragenics shares reverse split on Monday, January 23rd 2023. The 1-60 reverse split was announced on Monday, January 23rd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, January 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

What other stocks do shareholders of Oragenics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oragenics investors own include Yunji (YJ) , MFA Financial (MFA) and

How do I buy shares of Oragenics?

Shares of OGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NYSE:OGEN

Oragenics (OGEN) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free OGEN Stock Alerts

$1.15

+0.07 (+6.48%)

(As of 04/18/2024 ET)

Compare

Today's Range: $1.11
▼
$1.16
50-Day Range: $1.08
▼
$6.14
52-Week Range: $1.02
▼
$7.74

Volume: 23,236 shs
Average Volume: 84,998 shs
Market Capitalization: $5.15 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Get Oragenics alerts:

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Oragenics Stock (NYSE:OGEN)

Oragenics, Inc., a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.

OGEN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

OGEN Stock News Headlines

April 17, 2024 | money.usnews.com

Oragenics Inc

April 16, 2024 | ca.finance.yahoo.com

Oragenics, Inc. (OGEN) Latest Stock News & Headlines - Yahoo Finance

April 18, 2024 | InvestorPlace (Ad)

The Next Nvidia?

The Next Nvidia? Wall Street legend has just uncovered one tiny Maryland company that could become the next Nvidia. Few in the media are talking about this story yet… but in the next 6 months that’s all they’ll talk about.

April 16, 2024 | americanbankingnews.com

Oragenics (NYSE:OGEN) Coverage Initiated by Analysts at StockNews.com

April 8, 2024 | americanbankingnews.com

Oragenics (NYSE:OGEN) Earns Sell Rating from Analysts at StockNews.com

April 1, 2024 | finance.yahoo.com

Oragenics, Inc. Files 10K and Provides Company Update

March 18, 2024 | markets.businessinsider.com

Oragenics Appoints Kelly As Chief Medical Officer

March 17, 2024 | finance.yahoo.com

15 Highest Quality Probiotics For Gut Health

April 18, 2024 | InvestorPlace (Ad)

The Next Nvidia?

March 5, 2024 | businesswire.com

Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion

March 1, 2024 | businesswire.com

Oragenics Announces Closing of Public Offering

March 1, 2024 | uk.investing.com

Oragenics announces public stock offering

February 28, 2024 | investorplace.com

Why Is Oragenics (OGEN) Stock Down 45% Today?

February 27, 2024 | markets.businessinsider.com

Oragenics Prices Public Offering Of 1.40 Mln Shares At $1.50/shr; Stock Plunges

February 27, 2024 | businesswire.com

Oragenics Announces Pricing of Public Offering

February 27, 2024 | marketwatch.com

Oragenics Shares Fall After Proposed Public Offering

February 27, 2024 | businesswire.com

Oragenics Announces Proposed Public Offering

February 12, 2024 | marketwatch.com

Oragenics CEO Murphy Leaves, President Redmond Named Interim Replacement

February 12, 2024 | finance.yahoo.com

Oragenics, Inc. Announces Leadership Transition

February 7, 2024 | finance.yahoo.com

Oragenics, Inc. Announces Expiration of Its Investment Banking Engagement Agreement

February 5, 2024 | finance.yahoo.com

Oragenics, Inc. Preparing for Phase II Clinical Trials to Treat Concussion

January 23, 2024 | msn.com

Oragenics terminates ATM offering program; shares jump

January 23, 2024 | finance.yahoo.com

Oragenics Announces Termination of At-The-Market Offering Program

January 6, 2024 | seekingalpha.com

OGEN, RLMD and ATXI among mid-day movers

January 2, 2024 | financialpost.com

Oragenics Completes Acquisition of Odyssey Health’s Neurological Assets

December 12, 2023 | finanznachrichten.de

Odyssey Health, Inc. Gains Shareholder Approval for Asset Sale with Oragenics, Inc.

November 6, 2023 | finance.yahoo.com

Oragenics, Inc. (UAV.F)

See More Headlines

Receive OGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oragenics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/29/2024
Today: 4/18/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NYSE:OGEN
CUSIP: N/A
CIK: 1174940
Web: www.oragenics.com
Phone: 813-286-7900
Fax: 813-286-7904
Employees: 6
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($9.25)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-20,660,000.00
Net Margins: N/A
Pretax Margin: -54,858.84%
Return on Equity: -397.35%
Return on Assets: -246.95%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.15
Quick Ratio: 2.15

Sales & Book Value

Annual Sales: $40,000.00
Price / Sales: 120.96
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.61 per share
Price / Book: 1.77

Miscellaneous

Outstanding Shares: 4,480,000
Free Float: 3,379,000
Market Cap: $4.84 million
Optionable: N/A
Beta: 0.31

The 10 Best AI Stocks to Own in 2024

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

Mr. Charles L. Pope CPA (Age 72)
Executive Chairman
Comp: $112.5k
Mr. Joseph Michael Redmond (Age 63)
President & Interim Principal Executive Officer
Ms. Janet Huffman (Age 52)
CFO, Secretary & Treasurer
Comp: $314.9k
Dr. James P. Kelly M.A.
M.D., Chief Medical Officer & Member of Scientific Advisor

Key Competitors

View All Competitors

Insiders

Fred Telling
Sold 3,500 shares
Total: $12,495.00 ($3.57/share)

View All Insider Transactions

OGEN Stock Analysis - Frequently Asked Questions

How have OGEN shares performed in 2024?: Oragenics' stock was trading at $6.1382 on January 1st, 2024. Since then, OGEN stock has decreased by 81.3% and is now trading at $1.15.
View the best growth stocks for 2024 here.
How were Oragenics' earnings last quarter?: Oragenics, Inc. (NYSE:OGEN) announced its quarterly earnings data on Friday, March, 29th. The company reported ($5.48) earnings per share for the quarter.
When did Oragenics' stock split?: Oragenics shares reverse split on Monday, January 23rd 2023. The 1-60 reverse split was announced on Monday, January 23rd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, January 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

What other stocks do shareholders of Oragenics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Oragenics investors own include Yunji (YJ), MFA Financial (MFA) and
How do I buy shares of Oragenics?: Shares of OGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:OGEN) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial